This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Cambridge Enterprise Limited. Active years: 2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2026
Title: Michael Gill: Inventor in Pancreatic Cancer Treatment
Introduction
Michael Gill is an inventor based in Cambridge, Great Britain. His work includes a patent application concerning a potential therapeutic approach to pancreatic cancer. The available information identifies one patent associated with him.
Latest Patents
Gill’s patent, “Treatment and Prognosis of Pancreatic Cancer,” describes using a CCR1 antagonist, or a pharmaceutically acceptable salt, hydrate, or solvate of one, to treat pancreatic cancer. The approach may combine the antagonist with other anti-tumour therapies, including gemcitabine, fluorouracil (5-FU), capecitabine, FOLFIRINOX, nab-paclitaxel, or combinations of these agents. The patent also describes possible use alongside immuno-oncology treatments, such as PD-1 or PD-L1 inhibitors. Gill is associated with 1 patent.
Career Highlights
Gill is associated with Cambridge Enterprise Limited. His listed patent focuses on a combination-based treatment strategy for pancreatic cancer, involving CCR1 antagonism and established or emerging anti-tumour therapies.
Collaborations
The listed coworkers associated with Gill include Tony James Wu and Martin Miller. The available information does not specify their roles in the patent or their particular contributions.
Conclusion
Michael Gill’s patent work, associated with Cambridge Enterprise Limited, explores CCR1 antagonists and combination therapies as a potential approach to treating pancreatic cancer.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile